$ZOM "Following the commercial launch to TRUFORMA, we expect to continue the development of another point-of-care diagnostic platform, which is based on miniaturized laser-based Raman spectroscopy technology and is designed to detect pathogens in companion animals....." and ".... We have performed initial development work on a circulating tumor cell (CTC) "liquid biopsy" platform for use in a reference lab setting as a canine cancer diagnostic. This platform is intended for use to detect canine cancer faster, more affordably and less invasively compared to existing methods, which can be expensive and cost-prohibitive for pet owners....." -Zomedica Form 10-Q 2020-11-12
  • 7